Axonics Inc
NASDAQ:AXNX

Watchlist Manager
Axonics Inc Logo
Axonics Inc
NASDAQ:AXNX
Watchlist
Price: 70.98 USD 0.04% Market Closed
Market Cap: 3.6B USD
Have any thoughts about
Axonics Inc?
Write Note

Axonics Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Axonics Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Axonics Inc
NASDAQ:AXNX
Depreciation & Amortization
$12.5m
CAGR 3-Years
21%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Depreciation & Amortization
$2.3B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
15%
Boston Scientific Corp
NYSE:BSX
Depreciation & Amortization
$1.2B
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Depreciation & Amortization
$1B
CAGR 3-Years
2%
CAGR 5-Years
6%
CAGR 10-Years
11%
Abbott Laboratories
NYSE:ABT
Depreciation & Amortization
$3.2B
CAGR 3-Years
-3%
CAGR 5-Years
1%
CAGR 10-Years
7%
Intuitive Surgical Inc
NASDAQ:ISRG
Depreciation & Amortization
$497.9m
CAGR 3-Years
15%
CAGR 5-Years
22%
CAGR 10-Years
21%
No Stocks Found

Axonics Inc
Glance View

Market Cap
3.6B USD
Industry
Health Care

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 517 full-time employees. The company went IPO on 2018-10-31. The company is engaged in developing and commercializing products for patients with bladder and bowel dysfunction. The bladder and bowel dysfunction includes implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR), and a urethral bulking agent to treat female stress urinary incontinence (SUI). The company has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company has two relating to its r-SNM System, a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. The company offers urethral bulking agent, Bulkamid for stress urinary incontinence.

AXNX Intrinsic Value
33.81 USD
Overvaluation 52%
Intrinsic Value
Price

See Also

What is Axonics Inc's Depreciation & Amortization?
Depreciation & Amortization
12.5m USD

Based on the financial report for Sep 30, 2024, Axonics Inc's Depreciation & Amortization amounts to 12.5m USD.

What is Axonics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
61%

Over the last year, the Depreciation & Amortization growth was 3%. The average annual Depreciation & Amortization growth rates for Axonics Inc have been 21% over the past three years , 61% over the past five years .

Back to Top